Global office locator

What if you could cut development timelines by up to 12+ months while reducing costs and operational complexity? At #CPHIMilan, discover how ICON's Manufacturing & Pharmacy Services combine formulation development, GMP m...

A new cross-specialty framework is reshaping how MASLD developers think about patient identification. The 2026 cardiovascular-kidney-metabolic (CKM) syndrome guidelines endorse PREVENT equations that standardise multi-or...

AI is transforming medical writing, but should it replace experts? For complex regulatory documents such as clinical study reports (CSRs), scientific judgement, interpretation and accountability remain essential. In our...

The EU Packaging and Packaging Waste Regulation (PPWR) is reshaping packaging requirements across pharma and medtech. From sustainable packaging and harmonised labelling to new technical and digital requirements, organis...

Join ICON Biotech at OCT Southern California on 15–16 September at the Hyatt Regency La Jolla at Aventine, San Diego. Visit our team at Booth \#26. We welcome the opportunity to connect with biotech sponsors to discuss ...

Before restricting a trial to “marker‑positive” patients, developers must ask whether they’re excluding people who could still benefit, and potentially shrinking their future label. ICON’s Peter Schueler and Jack Martin ...

Robust statistical analysis plans are essential for the appropriate reporting of clinical trials and the reproducibility of findings, particularly for cell and cell-based gene therapies, where treatment pathways and outc...

Shift the publishing odds to your favour. Journals & Congresses offers comparable rejection rate insights. Review rejection rates by journal to better target the right fit for your submission. Check out our interactive d...

Clinical trials are becoming more complex, but complexity does not have to mean inefficiency. As study demands increase, sponsors need better visibility, stronger site engagement and operational intelligence that suppor...

The landscape for obesity therapeutics is expanding to address critical limitations of first-gen GLP-1s. There are now over 100 active obesity-specific clinical trials worldwide, with more than 60 in phase II/III stages....

ICON invites you to connect with our biomarker experts at WorldCDx. From biomarker discovery to diagnostic readiness we deliver integrated precision medicine solutions for clinical development. We work across all major p...

We're proud to share that ICON has been named one of TIME's World's Best Companies for the fourth consecutive year. This recognition reflects the expertise, commitment, and collaboration of our colleagues around the wor...